Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2018

View Archived Issues

Glycosylation of allergens increases immune tolerance following immunization

Finding improves stem cell safety

GABA impairment not down to lack of receptors in ASD

Antigen loss, CAR gain can cause resistance to CAR T therapy

Thalidomide analogue DAID safely and effectively reduces ocular neovascularization in rats

Autologous fecal microbiota transplant restores intestinal microbiota after antibiotic treatment

Olfactory ensheathing cells can deliver therapeutic transgenes to gliomas through the nasal pathway

Merck & Co. presents phase I data for RSV MAb MK-1654

Nymox reports 78-month results from phase IIb prostate cancer study of fexapotide triflutate

M72/AS01 shows efficacy in reducing tuberculosis cases in previously infected HIV-negative adults

First patient enrolled in REIMAGINE phase IIa study of vafidemstat

AgeneBio obtains grants to support phase III study of AGB-101

Cancer drugs may be repurposed for inflammation

Forskolin-induced swelling of intestinal organoids classifies cystic fibrosis disease severity

Acceleron presents preliminary phase II data for ACE-083 in patients with CMT

First-in-human data presented for branaplam in SMA type 1

Neurocrine Biosciences and Jnana collaborate to treat CNS disorders

Newly developed IgA nephropathy murine model shows autoimmune character

Wave Life Sciences to design products for rare inherited eye diseases

Biohaven licenses therapeutic antibody from University of Connecticut

Advanced Proteome Therapeutics reports preclinical finding on antibody-amanitin conjugate

Lixte submits IND for phase Ib/II trial of LB-100 in MDS

Japanese JOINUS research program opens second public recruitment offering

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...